GO:0004610 phosphoacetylglucosamine mutase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004610 (phosphoacetylglucosamine mutase activity) catalyzes the reversible interconversion of N-acetyl-alpha-D-glucosamine 1-phosphate and N-acetyl-D-glucosamine 6-phosphate, a step in the UDP-GlcNAc biosynthesis pathway.
• The human enzyme is encoded by PGM3 (phosphoglucomutase 3); the recombinant human protein was functionally cloned and its essential catalytic residues identified by mutational analysis.
• PGM3 deficiency causes a glycosylation disorder with a notable T cell defect, linking this enzymatic activity to immune function.
• PGM3 regulates beta-catenin activity and promotes colorectal cancer cell progression, and is a candidate therapeutic target in KRAS/LKB1 co-mutant lung cancer.
• In parasites such as Giardia intestinalis, the enzyme participates in cyst wall polysaccharide biosynthesis and is transcriptionally regulated during encystation.
• In insects, chitinase affects molting development by regulating chitin and trehalose metabolism, a process that depends on UDP-GlcNAc supply from this activity.
Description
Phosphoacetylglucosamine mutase activity (GO:0004610) is a molecular function that catalyzes the reversible conversion of N-acetyl-alpha-D-glucosamine 1-phosphate to N-acetyl-D-glucosamine 6-phosphate. This reaction is a key step in the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), the activated sugar donor used for protein glycosylation, glycosaminoglycan synthesis, and chitin formation. Because UDP-GlcNAc is required for a wide range of cellular processes, the enzyme that carries out this interconversion is of broad interest to researchers in glycobiology, immunology, cancer biology, and parasitology.
phosphoacetylglucosamine mutase activity At A Glance
| GO ID | GO:0004610 |
|---|---|
| GO term | phosphoacetylglucosamine mutase activity |
| Ontology | molecular_function |
| Synonym | acetylaminodeoxyglucose phosphomutase activity; acetylglucosamine phosphomutase activity; N-acetyl-alpha-D-glucosamine 1,6-phosphomutase activity; N-acetyl-D-glucosamine 1,6-phosphomutase activity; N-acetylglucosamine-phosphate mutase activity; phospho-N-acetylglucosamine mutase activity |
| Major function | Catalyzes the reversible interconversion of N-acetyl-alpha-D-glucosamine 1-phosphate and N-acetyl-D-glucosamine 6-phosphate, a step in UDP-GlcNAc biosynthesis. |
| Human gene | PGM3 (phosphoglucomutase 3) encodes the human enzyme. |
| Pathway context | UDP-GlcNAc biosynthesis; required for protein glycosylation and chitin synthesis. |
| Disease relevance | PGM3 deficiency causes a glycosylation disorder with T cell defect; PGM3 is implicated in colorectal and lung cancer. |
What Is GO:0004610?
Phosphoacetylglucosamine mutase activity (GO:0004610) is defined as the catalysis of the reaction: N-acetyl-alpha-D-glucosamine 1-phosphate = N-acetyl-D-glucosamine 6-phosphate. In other words, it is an intramolecular phosphotransferase (mutase) that moves a phosphate group between the 1 and 6 positions of N-acetylglucosamine, allowing the cell to interconvert these two sugar-phosphate isomers.
Why Is phosphoacetylglucosamine mutase activity Important in Cell Biology?
Phosphoacetylglucosamine mutase activity is important because it supplies the precursor for UDP-GlcNAc, a central metabolite in glycosylation and cell wall or chitin biosynthesis. Defects in the human enzyme cause a congenital disorder of glycosylation with immune deficiency, and altered activity has been linked to cancer progression and to parasite development.
• Provides N-acetyl-D-glucosamine 6-phosphate for UDP-GlcNAc synthesis, a key donor for protein glycosylation.
• Human PGM3 mutations cause a glycosylation disorder with notable T cell defect.
• PGM3 regulates beta-catenin activity and promotes colorectal cancer cell progression.
• PGM3 is a potential therapeutic target in KRAS/LKB1 co-mutant lung cancer.
• In Giardia intestinalis, the enzyme is involved in cyst wall polysaccharide biosynthesis and is transcriptionally regulated during encystation.
• In insects, chitinase affects molting by regulating chitin and trehalose metabolism, which depends on UDP-GlcNAc supply.
• The enzyme is conserved from yeast to humans, making it a tractable model for studying glycosylation pathways.
• Its catalytic residues have been identified, enabling structure-function studies.
Molecular Mechanism of phosphoacetylglucosamine mutase activity
Substrate binding and isomerization
In simple terms: The enzyme grabs a sugar-phosphate molecule and flips the phosphate from one position to another.
Phosphoacetylglucosamine mutase binds N-acetyl-alpha-D-glucosamine 1-phosphate and catalyzes its conversion to N-acetyl-D-glucosamine 6-phosphate. This reversible isomerization is essential for channeling glucosamine derivatives into UDP-GlcNAc biosynthesis.
Catalytic residues
In simple terms: Specific amino acids in the enzyme do the chemical work.
Mutational analysis of the human cDNA for phosphoacetylglucosamine mutase identified amino acid residues essential for catalysis, confirming the enzyme's catalytic mechanism.
Role in UDP-GlcNAc biosynthesis
In simple terms: This enzyme is one step in making a key sugar donor for glycosylation.
The reaction product N-acetyl-D-glucosamine 6-phosphate is further converted to UDP-GlcNAc, which is used for protein glycosylation and for chitin synthesis in fungi and insects.
Regulation in parasites
In simple terms: In some parasites, the enzyme is turned on when they form cysts.
In Giardia intestinalis, transcription of the gene encoding this activity is regulated during encystation, and galactosamine-synthesizing enzymes are induced when Giardia encysts.
Key Genes Involved in GO:0004610 phosphoacetylglucosamine mutase activity
The following genes and proteins are directly or indirectly associated with phosphoacetylglucosamine mutase activity (GO:0004610) and its pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PGM3 | Encodes human phosphoacetylglucosamine mutase; catalyzes the interconversion of GlcNAc-1-P and GlcNAc-6-P | Mutations cause glycosylation disorder with T cell defect; implicated in cancer |
| GNPNAT1 | Phosphoglucosamine mutase, upstream of PGM3 in UDP-GlcNAc biosynthesis | Target for studying glycosylation pathway flux |
| UAP1 | UDP-N-acetylglucosamine pyrophosphorylase, uses GlcNAc-1-P produced by PGM3 | Enzyme in UDP-GlcNAc biosynthesis |
| GFAT1 | Glutamine:fructose-6-phosphate amidotransferase, rate-limiting for hexosamine pathway | Regulates flux into UDP-GlcNAc |
| GFAT2 | Isoform of GFAT, contributes to hexosamine biosynthesis | Tissue-specific regulation |
| PGM1 | Phosphoglucomutase 1, related mutase with different substrate specificity | Comparative studies of mutase family |
| PGM2 | Phosphoglucomutase 2, related enzyme | Mutase family evolution |
| CHI | Chitinase, affects molting by regulating chitin and trehalose metabolism | Insect development studies |
| UDP-GlcNAc pyrophosphorylase | Converts GlcNAc-1-P to UDP-GlcNAc | Pathway enzyme |
| Chitin synthase | Polymerizes GlcNAc into chitin, requiring UDP-GlcNAc | Fungal and insect cell wall synthesis |
| O-GlcNAc transferase (OGT) | Uses UDP-GlcNAc for protein O-GlcNAcylation | Signaling and epigenetics |
| O-GlcNAcase (OGA) | Removes O-GlcNAc from proteins | Balances O-GlcNAcylation |
| beta-catenin | Regulated by PGM3 to promote colorectal cancer progression | Cancer signaling |
| KRAS | Co-mutant with LKB1 in lung cancer where PGM3 is a therapeutic target | Targeted therapy |
| LKB1 (STK11) | Co-mutant with KRAS; PGM3 targeting in this context | Lung cancer biology |
| Giardia PGM | Phosphoacetylglucosamine mutase in Giardia intestinalis, regulated during encystation | Parasite cyst wall synthesis |
| Yeast PGM | Enzymes of UDP-GlcNAc biosynthesis in yeast | Model organism for pathway studies |
How Is phosphoacetylglucosamine mutase activity Regulated?
Transcription of the gene encoding phosphoacetylglucosamine mutase is regulated during Giardia intestinalis encystation, and galactosamine-synthesizing enzymes are induced when Giardia encysts. In humans, PGM3 expression and activity influence beta-catenin signaling in colorectal cancer cells.
phosphoacetylglucosamine mutase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PGM3 | Glycosylation disorder with T cell defect | Knockout or point-mutation in T cells or patient-derived iPSCs |
| PGM3 | Colorectal cancer progression via beta-catenin | Knockout in colorectal cancer cell lines (e.g., HCT116) |
| PGM3 | KRAS/LKB1 co-mutant lung cancer | Knockout or overexpression in lung cancer cell lines |
| Giardia PGM | Cyst wall polysaccharide biosynthesis | Knockout in Giardia intestinalis |
| CHI | Insect molting development | Knockout in Spodoptera frugiperda |
PGM3 deficiency: a glycosylation disorder with T cell defect
PGM3 insufficiency causes a glycosylation disorder characterized by a notable T cell defect, highlighting the importance of phosphoacetylglucosamine mutase activity in immune function.
PGM3 in colorectal cancer
PGM3 regulates beta-catenin activity to promote colorectal cancer cell progression, suggesting that this enzymatic activity contributes to cancer cell proliferation.
PGM3 as a therapeutic target in lung cancer
Targeting PGM3 has been proposed as a novel therapeutic strategy in KRAS/LKB1 co-mutant lung cancer, linking this metabolic activity to precision oncology.
Parasite development and cyst formation
In Giardia intestinalis, the enzyme participates in cyst wall polysaccharide biosynthesis and is transcriptionally regulated during encystation, making it a potential target for antiparasitic strategies.
From phosphoacetylglucosamine mutase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PGM3 affect T cell development? | PGM3 knockout in Jurkat or primary T cells |
| Does a specific PGM3 point mutation alter catalytic activity? | Point-mutation knock-in in HEK293T cells |
| Does PGM3 overexpression drive colorectal cancer progression? | PGM3 overexpression in HCT116 cells |
| Does PGM3 knockout affect beta-catenin signaling? | PGM3 knockout in colorectal cancer cell lines |
| Does PGM3 inhibition sensitize KRAS/LKB1 co-mutant lung cancer? | PGM3 knockout or inhibitor treatment in lung cancer cells |
| Does PGM3 tagging affect localization? | Tagged knock-in (e.g., GFP) in HeLa cells |
How to Study the phosphoacetylglucosamine mutase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay | Interconversion of GlcNAc-1-P and GlcNAc-6-P | Measure PGM3 activity in cell lysates |
| Site-directed mutagenesis | Effect of point mutations on catalysis | Identify essential residues |
| RNA-seq | Transcript levels of PGM3 and pathway genes | Study regulation during encystation |
| CRISPR knockout screen | Gene essentiality and pathway dependencies | Identify glycosylation genes |
| Western blot | Protein expression of PGM3 | Validate knockout or overexpression |
| Mass spectrometry | UDP-GlcNAc levels | Metabolic profiling |
| Flow cytometry | T cell development and glycosylation | Assess immune defect |
| Immunofluorescence | Subcellular localization of tagged PGM3 | Tagged knock-in studies |
Enzymatic assays
Phosphoacetylglucosamine mutase activity can be measured by monitoring the interconversion of N-acetyl-alpha-D-glucosamine 1-phosphate and N-acetyl-D-glucosamine 6-phosphate using coupled enzymatic assays or mass spectrometry.
Mutational analysis
Site-directed mutagenesis of the human PGM3 cDNA followed by enzymatic assays identifies residues essential for catalysis.
Transcriptional profiling
RNA-seq or qPCR can measure regulation of the gene encoding this activity during processes such as Giardia encystation.
CRISPR screens
Genome-wide CRISPR knockout screens can identify genes whose loss affects UDP-GlcNAc biosynthesis or glycosylation, including PGM3.
How CRISPR Can Be Used to Study GO:0004610 phosphoacetylglucosamine mutase activity
Knockout
CRISPR knockout of PGM3 can be used to study loss of phosphoacetylglucosamine mutase activity, leading to reduced UDP-GlcNAc and glycosylation defects, as seen in PGM3 insufficiency.
Point Mutation
Point mutations in PGM3 catalytic residues can be introduced to dissect the enzymatic mechanism and to model patient mutations associated with glycosylation disorders.
Knock-in
Knock-in of tagged PGM3 (e.g., GFP or FLAG) allows visualization and immunoprecipitation of the enzyme to study its localization and interactions.
Overexpression
Overexpression of PGM3 can be used to test whether increased phosphoacetylglucosamine mutase activity promotes cancer cell progression, as observed in colorectal cancer.
How EDITGENE Supports phosphoacetylglucosamine mutase activity Research
Researchers studying phosphoacetylglucosamine mutase activity-related genes often need to determine whether a candidate gene is causally involved in glycosylation, immune function, or cancer progression. EDITGENE provides CRISPR-based cell model services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for phosphoacetylglucosamine mutase activity research.
Frequently Asked Questions About phosphoacetylglucosamine mutase activity
What is phosphoacetylglucosamine mutase activity?
Phosphoacetylglucosamine mutase activity (GO:0004610) is the catalysis of the reversible conversion of N-acetyl-alpha-D-glucosamine 1-phosphate to N-acetyl-D-glucosamine 6-phosphate, a step in UDP-GlcNAc biosynthesis.
What gene encodes phosphoacetylglucosamine mutase in humans?
The human enzyme is encoded by PGM3 (phosphoglucomutase 3).
What diseases are associated with PGM3 mutations?
PGM3 mutations cause a glycosylation disorder with a notable T cell defect, and PGM3 is implicated in colorectal and lung cancer.
How is phosphoacetylglucosamine mutase activity measured?
It can be measured by enzymatic assays monitoring the interconversion of GlcNAc-1-P and GlcNAc-6-P.
What is the role of PGM3 in cancer?
PGM3 regulates beta-catenin activity to promote colorectal cancer progression and is a therapeutic target in KRAS/LKB1 co-mutant lung cancer.
Is phosphoacetylglucosamine mutase conserved across species?
Yes, the enzyme is conserved from yeast to humans and is involved in UDP-GlcNAc biosynthesis.
What is the reaction catalyzed by GO:0004610?
The reaction is N-acetyl-alpha-D-glucosamine 1-phosphate = N-acetyl-D-glucosamine 6-phosphate.
How does PGM3 deficiency affect the immune system?
PGM3 insufficiency causes a glycosylation disorder with a notable T cell defect.
What model organisms are used to study phosphoacetylglucosamine mutase?
Giardia intestinalis, yeast, and insects such as Spodoptera frugiperda are used to study this activity in pathway contexts.
Can CRISPR be used to study PGM3 function?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect PGM3 function in cells.
Conclusion
Phosphoacetylglucosamine mutase activity (GO:0004610) is a conserved enzymatic step in UDP-GlcNAc biosynthesis with critical roles in glycosylation, immune function, and cancer. Its human gene PGM3 is linked to a glycosylation disorder and to cancer progression, making it a compelling target for functional studies. CRISPR-based cell models offer powerful tools to investigate this activity in health and disease.
References
- 1. Yang L et al.. 2024. PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect.. Front Immunol 15:1500381 PMID: 39776909
- 2. Liu XY et al.. 2022. Chitinase (CHI) of Spodoptera frugiperda affects molting development by regulating the metabolism of chitin and trehalose.. Front Physiol 13:1034926 PMID: 36262255
- 3. Mio T et al.. 2000. Functional cloning and mutational analysis of the human cDNA for phosphoacetylglucosamine mutase: identification of the amino acid residues essential for the catalysis.. Biochim Biophys Acta 1492(2-3):369-76 PMID: 11004509
- 4. Lopez AB et al.. 2003. Transcription regulation is demonstrated for five key enzymes in Giardia intestinalis cyst wall polysaccharide biosynthesis.. Mol Biochem Parasitol 128(1):51-7 PMID: 12706796
- 5. Milewski S et al.. 2006. Enzymes of UDP-GlcNAc biosynthesis in yeast.. Yeast 23(1):1-14 PMID: 16408321
- 6. Macechko PT et al.. 1992. Galactosamine-synthesizing enzymes are induced when Giardia encyst.. Mol Biochem Parasitol 56(2):301-9 PMID: 1484552
- 7. Zhang N et al.. 2022. PGM3 regulates beta-catenin activity to promote colorectal cancer cell progression.. Exp Biol Med (Maywood) 247(17):1518-1528 PMID: 35723049
- 8. Lee H et al.. 2022. Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer.. Cells 11(1) PMID: 35011738
